Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Conditions

• Relapsing Multiple Sclerosis

Interventions

• BIOLOGICAL: Ofatumumab
• BIOLOGICAL: Tetanus toxoid (TT) containing vaccine (Td, Tdap)
• BIOLOGICAL: 13-valent pneumococcal conjugate vaccine (13-PCV)
• BIOLOGICAL: 23-valent pneumococcal polysaccharide vaccine (23-PPV)
• BIOLOGICAL: Seasonal Quadrivalent influenza vaccine
• BIOLOGICAL: Keyhole limpet hemocyanin (KLH) neo-antigen

Sponsor

Novartis Pharmaceuticals